Compare Enveric Biosciences Inc (ENVB) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Vanguard Total International Stock Index Fund ETF trades at $84.69 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 97897.1× Enveric Biosciences Inc's market cap, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| ENVB | VXUS | |
|---|---|---|
Market Cap | $6.80M | $665.70B |
Volume | 64,867 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $10.80 | $88.41 |
52-Week Low | $1.27 | $72.17 |
Typical Hold Time | 14 Days | 55 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
VXUS trades at $84.67, down 0.13% with a bearish technical signal from moving averages and oscillators. The ETF provides diversified international stock exposure excluding U.S. markets, with recent institutional buying interest from firms like QRG Capital and Baird Financial. Support levels cluster around $83-84 while resistance sits at $85.
The outlook remains cautious given technical bearishness, though long-term diversification benefits and institutional accumulation provide support. Key risks include foreign market volatility and currency fluctuations, while the absence of U.S. exposure offers portfolio hedging advantages during domestic downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
